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survey, the study sample consisted of consec-
utive patients hospitalized for coronary artery 
bypass grafting or percutaneous coronary inter-
vention, or myocardial infarction, or unstable 
angina. As the age limit in the first (1997–1998) 
and the second (1999–2000) surveys was set be-
low 71 years at the time of hospitalization, we 
excluded all older participants of the other 3 sur-
veys from the present analysis.
The examination took part 6 to 18 months 
after the index hospitalization. Data on med-
ications were obtained using a standard ques-
tionnaire and were based on the study patients’ 
declarations. Survey protocols were approved 
by the institutional bioethics committee. All pa-
tients signed an informed consent form.
Statistical analysis Categorical variables were 
expressed as percentages, and continuous vari-
ables, as mean (SD). The Pearson χ2 test was ap-
plied to all categorical variables. Normally dis-
tributed continuous variables were compared 
using the analysis of variance. Variables with 
non-normal distribution were evaluated using 
the Kruskal–Wallis analysis of variance. A gen-
eralized linear model (logit model), as imple-
mented in the Statistica 13 software (TIBCO 
Software, Palo Alto, California, United States), 
Introduction Cardiovascular disease is 
the leading cause of death in developed coun-
tries.1 Recent years have shown that mortali-
ty rates following myocardial infarction (MI) 
remain high—amounting to about 10% with-
in a year after MI—despite the development of 
pharmacological and invasive methods of coro-
nary artery disease (CAD) treatment.2 The main 
causes of high mortality following MI, among 
others, include unsatisfactory control of risk 
factors, insufficient lifestyle changes, and inad-
equate pharmacotherapy.3 Secondary prevention 
of cardiovascular events relies on lifestyle mod-
ification, risk factor control, and optimal phar-
macotherapy.4 ‑7 The aim of the present analysis 
was to assess trends regarding the use of the ma-
jor drug classes in patients with chronic coro-
nary syndromes within 2 decades.
Methods We analyzed the data of individuals 
who took part in 5 surveys assessing secondary 
prevention following hospitalization due to CAD, 
carried out in the years 1997–1998, 1999–2000, 
2006–2007, 2011–2013, and  2016-2017.8 ‑1 2 
The same 5 hospitals serving the city and sur-
rounding districts participated in each survey. 
Methods used in surveys were published else-
where and looked similar.8 ‑13 Shortly, in each 
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the control of main risk factors and optimal 
pharmacotherapy.4,6,7 Our analysis provided ev-
idence for a substantial improvement with re-
spect to all drug classes, which improves prog-
nosis in patients with CAD, including postin-
farction patients and those with heart failure. 
The differences found in drug use could not be 
explained by differences in the mean age and ed-
ucation only. It seems that the increasing drug 
uptake reflects both the increasing prevalence of 
hypertension, heart failure, diabetes, and oth-
er diseases as well as improvement in the qual-
ity of treatment of these conditions. Interest-
ingly, larger differences could be seen in the de-
cade 1997 / 1998–2006 / 2007 than in the years 
2006 / 2007–2016 / 2017. This could be related to 
the rising awareness regarding the significance 
of guideline implementation at the beginning of 
the current century. It should be, however, em-
phasized that despite a considerable increase 
in cardiovascular drug use over the 20-year pe-
riod, the wider use of “newly” developed drugs, 
including protein convertase subtilisin / kexin 
type 9 inhibitors, type 2 renal sodium -glucose 
cotransporter inhibitors, ticagrelor, new anti-
thrombotic agents, and angiotensin receptor–
neprilysin inhibitor, could further decrease car-
diovascular risk. In addition, our findings should 
be interpreted in the light of studies that show 
high rates of CAD patients with uncontrolled 
risk factors.13‑15
Numerous studies assessing the quality of 
medical care in the field of secondary preven-
tion of CAD, including the prescription rates 
was used to compare proportions of patients us-
ing drugs from particular classes, and the mod-
el was adjusted for sex, age, education, and in-
dex event. A 2-tailed P value less than 0.05 was 
considered significant.
Results and discussion The number of survey 
participants was as follows: 418 in 1997–1998, 
427 in 1999–2000, 425 in 2006–2007, 469 in 
2011–2013, and 274 in 2016–2017. The mean (SD) 
age of the study participants was 57.8 (8.3) years 
in 1997–1998, 58.6 (8.1) years in 1999–2000, 
59.9 (7.6) years in 2006–2007, 61.1 (6.9) years 
in 2011–2013, and 62.6 (6.9) years in 2016–2017 
(P <0.001). There was no significant difference in 
sex distribution between surveys (in total, 70.9% 
of men and 29.1% of women), whereas the mean 
(SD) duration of education gradually increased: 
11.4 (3.6) years in 1997–1998, 11.6 (3.5) years in 
1999–2000, 11.9 (3.4) years in 2006–2007, 12.1 
(3.1) years in 2011–2013, and 13 (3.1) years in 
2016–2017 (P <0.001).
Crude proportions of patients taking an-
tiplatelet agents, β  -blockers, angiotensin-
-converting enzyme inhibitors / sartans, calci-
um antagonists, diuretics, anticoagulants, lipid-
-lowering drugs, and antidiabetic agents are pre-
sented in TABLE 1. In univariate analysis, we ob-
served significant differences in the use of all 
analyzed drug classes. Multivariate adjustments 
did not influence the results significantly (TABLE 1).
Evidence suggests that survival in patients 
with CAD may be improved through providing 
optimal secondary prevention, which includes 
Table 1 Prescription rates of drug classes at 6 to 18 months after hospitalization due to the index event











Antiplatelets (at least 1 agent) 76.1 86.9 90.1 90 96.7 <0.001
β­‑Blockers 59.1 63.9 87.5 80.8 92.7 <0.001
ACEIs­/­sartans Any 45.9 47.5 79 76.8 89.1 <0.001
ACEIs 45.9 47.5 74.6 66.1 74.8 <0.001
Sartans 0 0 5.4 12.6 14.2 <0.001
Calcium­antagonists 28.7 33.3 20.9 21.1 27.7 <0.001
Diuretics 17 21 31.8 36.3 41.2 <0.001
Lipid‑lowering­drugs Any 33.7 41.9 86.8 83.4 90.8 <0.001
Statins 19.4 34.2 85.4 83.2 90.5 <0.001
Fibrates 14.1 7.7 3.5 2.6 1.1 <0.001
Ezetimibe 0 0 0.2 0.6 3.3 <0.001
Antidiabetic­agents 10.3 13.4 19.6 25.6 34.3 <0.001
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of cardiovascular drugs, have been published 
so far.13,14 To our best knowledge, the present 
study analyzed the only available data that al-
low one to estimate the operational efficien-
cy of the same hospitals in the secondary pre-
vention of CAD over 20 years. This provides 
a unique opportunity to track long -term chang-
es in prescription rates in patients with CAD 
who lived in a defined area and were hospital-
ized in the same hospitals.
Admittedly, our analysis had several limi-
tations. Although our results were obtained 
from consecutive surveys conducted in patients 
with established CAD who were inhabitants of 
the same area, the observation was restricted 
to those who experienced an acute CAD event 
or underwent a revascularization procedure. 
Therefore, the study participants were not rep-
resentative of all patients with CAD and the ap-
plicability of the results to other regions re-
mains uncertain. On the other hand, the dem-
onstrated trends correspond with short -term 
changes observed in patients with CAD in other 
European countries.15 Study groups could dif-
fer with respect to the number of unidentified 
factors, which could explain the discrepancies. 
It also needs to be noted that most of the ana-
lyzed drug classes should be prescribed in par-
ticular conditions depending on left ventricu-
lar function, blood pressure, glucose metabo-
lism, heart rate, presence of angina or arrhyth-
mia, etc. Therefore, one should not expect that 
agents from a particular drug class were pre-
scribed in 100% of the analyzed patients.
In conclusion, the analysis of 5 multicenter 
surveys provided evidence for a gradual increase 
in the uptake of the major groups of cardiovas-
cular drugs in patients with chronic coronary 
syndromes over a 20-year period.
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